Xtant医疗推出性能卓越的Trivium™高级骨移植产品-动脉网

Xtant Medical Launches Trivium™ Advanced Bone Graft for Superior Performance

CISION 等信源发布 2025-04-23 20:00



可切换为仅中文







BELGRADE, Mont.

贝尔格莱德，蒙大拿州

，

April 23, 2025

2025年4月23日

/PRNewswire/ -- Xtant Medical Holdings, Inc.(NYSE American:XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal, orthopedic and woundcare disorders, is proud to announce the launch of

/PRNewswire/ -- Xtant Medical Holdings, Inc.（纽约证券交易所代码：XTNT）是一家全球医疗技术公司，专注于脊柱、骨科和伤口护理疾病的手术解决方案，自豪地宣布推出

Trivium™

, a premium, next-generation demineralized bone matrix (DBM) allograft designed to elevate the standard of care in bone grafting procedures. Engineered with advanced PureLoc™ Fiber Technology, Trivium combines three synergistic elements intended to deliver exceptional performance in structure, handling, and biological activity..

，一种优质的下一代脱矿骨基质（DBM）同种异体移植物，旨在提升骨移植手术的护理标准。Trivium采用先进的PureLoc™纤维技术，结合了三种协同元素，旨在结构、操作和生物活性方面提供卓越性能。

继续阅读

Trivium is uniquely designed, featuring intertwined structures and interconnected porosity that support the attachment and proliferation of a variety of cell types, and designed to promote robust tissue ingrowth. This advanced composition creates an ideal environment for healing and regeneration.

Trivium 独特设计，具有相互交织的结构和相互连接的孔隙率，能够支持多种细胞类型的附着和增殖，并旨在促进强大的组织生长。这种先进的组成创造了理想的愈合和再生环境。

With its superior moldability and handling characteristics, Trivium allows surgeons to place the graft with precision across a wide range of surgical applications.

由于其卓越的可塑性和操作特性，Trivium使外科医生能够在广泛的应用中精确放置移植物。

Trivium is processed using Xtant's proprietary BacteRinse

Trivium 是使用 Xtant 专有的 BacteRinse 处理的

method, clinically proven over two decades to preserve native bone morphogenetic proteins (BMPs). This ensures Trivium delivers a complete suite of bioavailable growth factors critical to initiating and supporting bone repair.

方法，经过二十多年的临床验证，可以保存天然骨形态发生蛋白 (BMP)。这确保了Trivium提供一套完整的、生物可利用的生长因子，这些因子对启动和支持骨骼修复至关重要。

'Trivium represents a significant advancement in bone grafting technology,' said

“Trivium代表了骨移植技术的重大进步，”

Sean Browne

肖恩·布朗

, President and CEO of Xtant Medical. 'By combining enhanced composition, high BMP retention, and versatile handling characteristics, Trivium provides surgeons with a dependable solution for a variety of surgical applications. We are confident that Trivium will deliver consistent, reliable outcomes for patients.' .

，Xtant Medical的总裁兼首席执行官。“通过结合增强的成分、高BMP保留率和多样化的操作特性，Trivium为外科医生提供了针对各种手术应用的可靠解决方案。我们相信，Trivium将为患者带来一致且可靠的治疗效果。”

Trivium represents Xtant Medical's ongoing commitment to innovation in regenerative medicine, providing surgeons with a high-performance graft that supports optimal outcomes. Trivium is now available to the company's nationwide distribution network of independent agents.

Trivium 代表了 Xtant Medical 在再生医学领域持续创新的承诺，为外科医生提供了一种支持最佳效果的高性能移植物。Trivium 现已可供公司遍布全国的独立代理商分销网络使用。

About

关于

Xtant Medical Holdings, Inc.

Xtant医疗控股公司

Xtant Medical's mission of 'honoring the gift of donation so that our patients can live as full and complete a life as possible' is the driving force behind our company. Xtant Medical Holdings, Inc. (

Xtant Medical的使命是“尊重捐赠的礼物，以便我们的患者能够过上尽可能充实和完整的生活”，这是推动我们公司发展的动力。Xtant Medical Holdings, Inc. (

www.xtantmedical.com

) is a global medical technology company focused on the design, development, and commercialization of a comprehensive portfolio of orthobiologics and spinal implant systems to facilitate spinal fusion in complex spine, deformity and degenerative procedures. Xtant people are dedicated and talented, operating with the highest integrity to serve our customers. .

）是一家全球医疗技术公司，专注于设计、开发和商业化全面的骨生物制品和脊柱植入系统组合，以促进复杂脊柱、畸形和退行性手术中的脊柱融合。Xtant 的员工专注且才华横溢，以最高的诚信为客户提供服务。

The symbols

符号

™

and

和

denote trademarks and registered trademarks of Xtant Medical Holdings, Inc. or its affiliates, registered as indicated in

表示Xtant Medical Holdings, Inc.或其附属公司的商标和注册商标，如所示已注册。

the United States

美国

, and in other countries. All other trademarks and trade names referred to in this release are the property of their respective owners.

，以及其他国家。本发布中提到的所有其他商标和商号均为其各自所有者的财产。

Cautionary Statement Regarding Forward-Looking Statements

关于前瞻性声明的警告性声明

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that are predictive in nature, that depend upon or refer to future events or conditions, or that include words such as 'intends,' ''expects,'' ''anticipates,'' ''plans,'' ''believes,'' ''estimates,'' 'continue,' 'future,' ''will,'' 'potential,' similar expressions or the negative thereof, and the use of future dates.

本新闻稿包含1995年《私人证券诉讼改革法案》意义上的前瞻性陈述。前瞻性陈述包括具有预测性质的陈述，取决于或涉及未来事件或条件的陈述，或包含诸如“打算”、“预期”、“预期”、“计划”、“相信”、“估计”、“继续”、“未来”、“将”、“潜在”等词语或类似表达或其否定形式的陈述，以及使用未来日期的情况。

Forward-looking statements in this release include the Company's expectations regarding the performance of Trivium and outcomes for patients utilizing Trivium. The Company cautions that its forward-looking statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others: the ability of newly launched products, such as Trivium, to gain market acceptance, perform as designed and intended, and meet the needs of surgeons and patients, including as a result of the lack of robust clinical validation; Xtant's ability to execute its strategic priorities and become operationally self-sustaining and less reliant on third-party manufacturers and suppliers; its ability to implement successfully future growth initiatives and risks associated therewith; its ability to remain competitive and innovate, develop and introduce new products and the success of those products; its ability to engage and retain new and existing independent distributors and agents and qualified personnel and its dependence on key independent agents for a significant portion of its revenue; the effect of labor and hospital staffing shortages on its business, operating results and financial condition, especially when they a.

本发布中的前瞻性声明包括公司对Trivium的表现及其为使用Trivium的患者带来的结果的预期。公司提醒，其前瞻性声明因其性质而涉及风险和不确定性，实际结果可能因多种重要因素而有重大差异，这些因素包括但不限于：新推出的产品（如Trivium）获得市场认可、按设计和预期表现并满足外科医生和患者需求的能力，特别是由于缺乏强有力的临床验证；Xtant执行其战略重点并实现运营自给自足及减少对第三方制造商和供应商依赖的能力；成功实施未来增长计划及其相关风险的能力；保持竞争力、创新、开发和推出新产品以及这些产品取得成功的能力；吸引和保留新的及现有的独立分销商和代理商及合格员工的能力，以及其对关键独立代理商产生相当大比例收入的依赖性；劳动力和医院人员短缺对其业务、经营结果和财务状况的影响，尤其是当他们……

December 31, 2024

2024年12月31日

filed with the Securities and Exchange Commission (SEC) on

向证券交易委员会（SEC）提交

March 6, 2025

2025年3月6日

and subsequent SEC filings by the Company. Investors are encouraged to read the Company's filings with the SEC, available at

并随后由公司提交给美国证券交易委员会的文件。鼓励投资者阅读公司在SEC的备案文件，可访问

www.sec.gov

, for a discussion of these and other risks and uncertainties. The Company undertakes no obligation to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law.

，有关这些及其他风险和不确定性的讨论。公司不承担公开发布对任何前瞻性声明的修订以反映本日期之后的事件或情况或反映未预期事件的发生的责任，除非法律要求。

All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by this cautionary statement. .

本公司或代表其行事的人员所有的前瞻性声明均应以本警示声明为准，完全符合其规定。

SOURCE Xtant Medical Holdings, Inc.

来源：Xtant Medical Holdings, Inc.

WANT YOUR COMPANY'S NEWS

想要你公司的新闻

FEATURED ON PRNEWSWIRE.COM?

荣登PRNEWSWIRE.COM？

440k+

44万+

Newsrooms &

新闻编辑室 &

Influencers